Market Capitalization

A green finance firm is investing in gas-powered data centers. Stephen Miller analyzes the $15M deal that reveals the pragmatic, and controversial, future of AI.

With audited reserves and public funds, exchanges are pushing for transparency. We dive deep into whether this new model for accountability can truly secure your assets.

Amid rising cyber threats, Toobit launches a security hub with verifiable Proof of Reserves. But does this bet on transparency truly redefine trust?

After 990 tense sessions and a recent strike, Colombia's energy giant secured a landmark 6-year labor deal. A look at the numbers reveals a strategic trade-off.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Defiance's new 2X SpaceX ETF arrives just after a record IPO, offering amplified returns. But are these complex products a new tool or a new trap?

Apollo Art Auctions' upcoming sale reveals how ancient artifacts are becoming a modern asset class, blending royal provenance with digital accessibility.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

Chaka Khan's partnership with HarbourView isn't just a deal; it's a look into the future of music, where finance and artistry create a new kind of legacy.

New research reveals AI engines are inventing 1 in 5 celebrity deals and warping financial reputations around single events, signaling a new corporate battleground.

With key hires from the semiconductor world and AWS, SambaNova isn't just growing. It's making a high-stakes bet on premium inference and autonomous AI.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

In markets like Paradise Valley, where location is king, a new trend emerges. High-value homeowners are investing heavily to elevate, not abandon, their irreplaceable properties.

The Chinese insurtech's massive share consolidation is a desperate bid to stay on Nasdaq, but it reveals deeper struggles facing Chinese ADRs in the US.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

As SpaceX makes its historic market debut, GraniteShares launches leveraged ETFs, offering traders a high-stakes way to bet on the volatile space pioneer.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

FCPT's latest acquisition seems minor, but it reveals a powerful strategy for navigating economic uncertainty by targeting essential, service-based real estate.

JAB's ~$1.8B sale of its final KDP stake isn't just an exit; it's a masterclass in capital reallocation towards a focused consumer brand empire.